{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T02:23:53Z","timestamp":1648866233936},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T00:00:00Z","timestamp":1527638400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s12020-018-1632-2","type":"journal-article","created":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T11:56:00Z","timestamp":1527681360000},"page":"271-273","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Primary hyperparathyroidism in prostate cancer: guilty or not guilty?"],"prefix":"10.1007","volume":"62","author":[{"given":"G.","family":"Mazziotti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Frara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,30]]},"reference":[{"issue":"3","key":"1632_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s12020-013-0113-x","volume":"45","author":"RA Adler","year":"2014","unstructured":"R.A. Adler, Prostate cancer treated with androgen deprivation therapy has consequences for bone. Endocrine 45(3), 339\u2013340 (2014). \n                    https:\/\/doi.org\/10.1007\/s12020-013-0113-x","journal-title":"Endocrine"},{"issue":"3","key":"1632_CR2","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s12020-013-0083-z","volume":"45","author":"ACM Lassemillante","year":"2014","unstructured":"A.-C.M. Lassemillante, S.A.R. Doi, J.D. Hooper, J.B. Prins, O.R.L. Wright, Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis. Endocrine 45(3), 370\u2013381 (2014). \n                    https:\/\/doi.org\/10.1007\/s12020-013-0083-z","journal-title":"Endocrine"},{"issue":"2","key":"1632_CR3","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s12020-015-0536-7","volume":"50","author":"ACM Lassemillante","year":"2015","unstructured":"A.-C.M. Lassemillante, S.A.R. Doi, J.D. Hooper, J.B. Prins, O.R.L. Wright, Prevalence of osteoporosis in prostate cancer survivors II: a meta-analysis of men not on androgen deprivation therapy. Endocrine 50(2), 344\u2013354 (2015). \n                    https:\/\/doi.org\/10.1007\/s12020-015-0536-7","journal-title":"Endocrine"},{"issue":"5","key":"1632_CR4","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1053\/hp.2000.6698","volume":"31","author":"L Bubendorf","year":"2000","unstructured":"L. Bubendorf, A. Schopfer, U. Wagner, G. Sauter, H. Moch, N. Willi, T.C. Gasser, M.J. Mihatsch, Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 31(5), 578\u2013583 (2000)","journal-title":"Hum. Pathol."},{"issue":"6","key":"1632_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrclinonc.2014.70","volume":"11","author":"BA Gartrell","year":"2014","unstructured":"B.A. Gartrell, F. Saad, Managing bone metastases and reducing skeletal related events in prostate cancer. Nat. Rev. Clin. Oncol. 11(6), 335\u2013345 (2014). \n                    https:\/\/doi.org\/10.1038\/nrclinonc.2014.70","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"1632_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10238-006-0117-4","volume":"6","author":"D Ribatti","year":"2006","unstructured":"D. Ribatti, G. Mangialardi, A. Vacca, Stephen Paget and the \u201cseed and soil\u201d theory of metastatic dissemination. Clin. Exp. Med. 6(4), 145\u2013149 (2006). \n                    https:\/\/doi.org\/10.1007\/s10238-006-0117-4","journal-title":"Clin. Exp. Med."},{"key":"1632_CR7","doi-asserted-by":"publisher","first-page":"405920","DOI":"10.1155\/2014\/405920","volume":"2014","author":"F Rahim","year":"2014","unstructured":"F. Rahim, S. Hajizamani, E. Mortaz, A. Ahmadzadeh, M. Shahjahani, S. Shahrabi, N. Saki, Molecular regulation of bone marrow metastasis in prostate and breast cancer. Bone Marrow Res. 2014, 405920 (2014). \n                    https:\/\/doi.org\/10.1155\/2014\/405920","journal-title":"Bone Marrow Res."},{"key":"1632_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbo.2017.09.001","volume":"9","author":"S D\u2019Oronzo","year":"2017","unstructured":"S. D\u2019Oronzo, J. Brown, R. Coleman, The role of biomarkers in the management of bone-homing malignancies. J. Bone Oncol. 9, 1\u20139 (2017). \n                    https:\/\/doi.org\/10.1016\/j.jbo.2017.09.001","journal-title":"J. Bone Oncol."},{"issue":"2","key":"1632_CR9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s12020-017-1351-0","volume":"59","author":"F Minisola","year":"2018","unstructured":"F. Minisola, C. Cipriani, L. Colangelo, M. Cilli, A. Sciarra, M. Von Heland, L. Nieddu, E. Anastasi, R. Pascone, V. Fassino, D. Diacinti, F. Longo, S. Minisola, J. Pepe, Mineral metabolism abnormalities in patients with prostate cancer: a systematic case controlled study. Endocrine 59(2), 338\u2013343 (2018). \n                    https:\/\/doi.org\/10.1007\/s12020-017-1351-0","journal-title":"Endocrine"},{"issue":"3","key":"1632_CR10","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1210\/jc.2012-4022","volume":"98","author":"MW Yeh","year":"2013","unstructured":"M.W. Yeh, P.H. Ituarte, H.C. Zhou, S. Nishimoto, I.L. Liu, A. Harari, P.I. Haigh, A.L. Adams, Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J. Clin. Endocrinol. Metab. 98(3), 1122\u20131129 (2013). \n                    https:\/\/doi.org\/10.1210\/jc.2012-4022","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"1632_CR11","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"N. Mottet, J. Bellmunt, M. Bolla, E. Briers, M.G. Cumberbatch, M. De Santis, N. Fossati, T. Gross, A.M. Henry, S. Joniau, T.B. Lam, M.D. Mason, V.B. Matveev, P.C. Moldovan, R.C.N. van den Bergh, T. Van den Broeck, H.G. van der Poel, T.H. van der Kwast, O. Rouviere, I.G. Schoots, T. Wiegel, P. Cornford, EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur. Urol. 71(4), 618\u2013629 (2017). \n                    https:\/\/doi.org\/10.1016\/j.eururo.2016.08.003","journal-title":"Eur. Urol."},{"issue":"2","key":"1632_CR12","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.bone.2006.01.146","volume":"39","author":"U Cinamon","year":"2006","unstructured":"U. Cinamon, R.E. Turcotte, Primary hyperparathyroidism and malignancy: \u201cstudies by nature\u201d. Bone 39(2), 420\u2013423 (2006). \n                    https:\/\/doi.org\/10.1016\/j.bone.2006.01.146","journal-title":"Bone"},{"issue":"5","key":"1632_CR13","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/oxfordjournals.aje.a114879","volume":"127","author":"M Palmer","year":"1988","unstructured":"M. Palmer, H.O. Adami, U.B. Krusemo, S. Ljunghall, Increased risk of malignant diseases after surgery for primary hyperparathyroidism. A nationwide cohort study. Am. J. Epidemiol. 127(5), 1031\u20131040 (1988)","journal-title":"Am. J. Epidemiol."},{"issue":"8","key":"1632_CR14","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1002\/cncr.10846","volume":"95","author":"AL Pickard","year":"2002","unstructured":"A.L. Pickard, G. Gridley, L. Mellemkjae, C. Johansen, A. Kofoed-Enevoldsen, K.P. Cantor, L.A. Brinton, Hyperparathyroidism and subsequent cancer risk in Denmark. Cancer 95(8), 1611\u20131617 (2002). \n                    https:\/\/doi.org\/10.1002\/cncr.10846","journal-title":"Cancer"},{"issue":"3","key":"1632_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/ijc.20155","volume":"110","author":"KB Michels","year":"2004","unstructured":"K.B. Michels, F. Xue, L. Brandt, A. Ekbom, Hyperparathyroidism and subsequent incidence of breast cancer. Int. J. Cancer 110(3), 449\u2013451 (2004). \n                    https:\/\/doi.org\/10.1002\/ijc.20155","journal-title":"Int. J. Cancer"},{"key":"1632_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejim.2017.06.001","volume":"43","author":"S Palmieri","year":"2017","unstructured":"S. Palmieri, L. Roggero, E. Cairoli, V. Morelli, A. Scillitani, I. Chiodini, C. Eller-Vainicher, Occurrence of malignant neoplasia in patients with primary hyperparathyroidism. Eur. J. Intern. Med. 43, 77\u201382 (2017). \n                    https:\/\/doi.org\/10.1016\/j.ejim.2017.06.001","journal-title":"Eur. J. Intern. Med."},{"issue":"3","key":"1632_CR17","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1054\/mehy.1999.0880","volume":"54","author":"MF McCarty","year":"2000","unstructured":"M.F. McCarty, Parathyroid hormone may be a cancer promoter\u2014an explanation for the decrease in cancer risk associated with ultraviolet light, calcium, and vitamin D. Med. Hypotheses 54(3), 475\u2013482 (2000). \n                    https:\/\/doi.org\/10.1054\/mehy.1999.0880","journal-title":"Med. Hypotheses"},{"issue":"3","key":"1632_CR18","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1677\/erc.0.0100403","volume":"10","author":"S Takahashi","year":"2003","unstructured":"S. Takahashi, M. Hakuta, K. Aiba, Y. Ito, N. Horikoshi, M. Miura, K. Hatake, E. Ogata, Elevation of circulating plasma cytokines in cancer patients with high plasma parathyroid hormone-related protein levels. Endocr. Relat. Cancer 10(3), 403\u2013407 (2003)","journal-title":"Endocr. Relat. Cancer"},{"key":"1632_CR19","unstructured":"F.C. Cackowski, R.S. Taichman, Parallels between hematopoietic stem cell and prostate cancer disseminated tumor cell regulation. Bone (2018). 10.1016\/j.bone.2018.02.025"},{"key":"1632_CR20","unstructured":"H. Huang, C. Wang, F. Liu, H.Z. Li, G. Peng, X. Gao, K.Q. Dong, H.R. Wang, D.P. Kong, M. Qu, L.H. Dai, K.J. Wang, Z. Zhou, J. Yang, Z.Y. Yang, Y.Q. Cheng, Q.Q. Tian, D. Liu, C.L. Xu, D.F. Xu, X.G. Cui, Y.H. Sun, Reciprocal network between cancer stem-like cells and macrophages facilitates the progression and androgen deprivation therapy resistance of prostate cancer. Clin. Cancer Res. (2018). 10.1158\/1078-0432.Ccr-18-0461"},{"issue":"4","key":"1632_CR21","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3892\/ijmm.2017.2900","volume":"39","author":"SA Bessa Garcia de","year":"2017","unstructured":"S.A. de Bessa Garcia, A.C. Pavanelli, E.M.N. Cruz, M.A. Nagai, Prostate apoptosis response 4 (PAR4) expression modulates WNT signaling pathways in MCF7 breast cancer cells: A possible mechanism underlying PAR4-mediated docetaxel chemosensitivity. Int. J. Mol. Med. 39(4), 809\u2013818 (2017). \n                    https:\/\/doi.org\/10.3892\/ijmm.2017.2900","journal-title":"Int. J. Mol. Med."},{"issue":"3","key":"1632_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/10409230290771483","volume":"37","author":"MF Leeman","year":"2002","unstructured":"M.F. Leeman, S. Curran, G.I. Murray, The structure, regulation, and function of human matrix metalloproteinase-13. Crit. Rev. Biochem. Mol. Biol. 37(3), 149\u2013166 (2002). \n                    https:\/\/doi.org\/10.1080\/10409230290771483","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"issue":"1","key":"1632_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1210\/er.2003-0024","volume":"26","author":"TM Murray","year":"2005","unstructured":"T.M. Murray, L.G. Rao, P. Divieti, F.R. Bringhurst, Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl- terminal ligands. Endocr. Rev. 26(1), 78\u2013113 (2005). \n                    https:\/\/doi.org\/10.1210\/er.2003-0024","journal-title":"Endocr. Rev."},{"issue":"5","key":"1632_CR24","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/0090-4295(94)90183-X","volume":"43","author":"M Iwamura","year":"1994","unstructured":"M. Iwamura, P.A. Abrahamsson, K.A. Foss, G. Wu, A.T. Cockett, L.J. Deftos, Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. Urology 43(5), 675\u2013679 (1994)","journal-title":"Urology"},{"issue":"19","key":"1632_CR25","doi-asserted-by":"publisher","first-page":"17291","DOI":"10.18632\/oncotarget.4174","volume":"6","author":"S Feng","year":"2015","unstructured":"S. Feng, J. Wang, Y. Zhang, C.J. Creighton, M. Ittmann, FGF23 promotes prostate cancer progression. Oncotarget 6(19), 17291\u201317301 (2015). \n                    https:\/\/doi.org\/10.18632\/oncotarget.4174","journal-title":"Oncotarget"},{"issue":"12","key":"1632_CR26","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.1210\/jc.2014-2821","volume":"99","author":"L Michaud","year":"2014","unstructured":"L. Michaud, A. Burgess, V. Huchet, M. Lefevre, M. Tassart, J. Ohnona, K. Kerrou, S. Balogova, J.N. Talbot, S. Perie, Is 18F-fluorocholine-positron emission tomography\/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism? J. Clin. Endocrinol. Metab. 99(12), 4531\u20134536 (2014). \n                    https:\/\/doi.org\/10.1210\/jc.2014-2821","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"1632_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s12020-008-9061-2","volume":"33","author":"R Scalco","year":"2008","unstructured":"R. Scalco, M.O. Premaor, P.E. Fr\u00f6ehlich, T.W. Furlanetto, High prevalence of hypovitaminosis D and secondary hyperparathyroidism in elders living in nonprofit homes in South Brazil. Endocrine 33(1), 95\u2013100 (2008). \n                    https:\/\/doi.org\/10.1007\/s12020-008-9061-2","journal-title":"Endocrine"},{"issue":"2","key":"1632_CR28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s12020-016-0960-3","volume":"53","author":"JC Souberbielle","year":"2016","unstructured":"J.-C. Souberbielle, C. Massart, S. Brailly-Tabard, E. Cavalier, P. Chanson, Prevalence and determinants of vitamin D deficiency in healthy French adults: the VARIETE study. Endocrine 53(2), 543\u2013550 (2016). \n                    https:\/\/doi.org\/10.1007\/s12020-016-0960-3","journal-title":"Endocrine"},{"key":"1632_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.bone.2017.01.013","volume":"97","author":"R Pedersini","year":"2017","unstructured":"R. Pedersini, S. Monteverdi, G. Mazziotti, V. Amoroso, E. Roca, F. Maffezzoni, L. Vassalli, F. Rodella, A.M. Formenti, S. Frara, R. Maroldi, A. Berruti, E. Simoncini, A. Giustina, Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: a cross-sectional study. Bone 97, 147\u2013152 (2017). \n                    https:\/\/doi.org\/10.1016\/j.bone.2017.01.013","journal-title":"Bone"},{"issue":"3","key":"1632_CR30","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1210\/jc.2017-01986","volume":"103","author":"G Mazziotti","year":"2018","unstructured":"G. Mazziotti, A.M. Formenti, S. Frara, R. Olivetti, G. Banfi, M. Memo, R. Maroldi, R. Giubbini, A. Giustina, High prevalence of radiological vertebral fractures in women on thyroid-stimulating hormone-suppressive therapy for thyroid carcinoma. J. Clin. Endocrinol. Metab. 103(3), 956\u2013964 (2018). \n                    https:\/\/doi.org\/10.1210\/jc.2017-01986","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"1632_CR31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12020-017-1455-6","volume":"59","author":"G Mazziotti","year":"2018","unstructured":"G. Mazziotti, A.M. Formenti, M.B. Panarotto, E. Arvat, A. Chiti, A. Cuocolo, M.E. Dottorini, C. Durante, L. Agate, S. Filetti, F. Felicetti, A. Filice, L. Pace, T. Pellegrino, M. Rodari, M. Salvatori, C. Tranfaglia, A. Versari, D. Viola, S. Frara, A. Berruti, A. Giustina, R. Giubbini, Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience. Endocrine 59(1), 90\u2013101 (2018). \n                    https:\/\/doi.org\/10.1007\/s12020-017-1455-6","journal-title":"Endocrine"},{"issue":"12","key":"1632_CR32","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1007\/s00198-013-2530-3","volume":"24","author":"R Rizzoli","year":"2013","unstructured":"R. Rizzoli, J.J. Body, M.L. Brandi, J. Cannata-Andia, D. Chappard, A. El Maghraoui, C.C. Gluer, D. Kendler, N. Napoli, A. Papaioannou, D.D. Pierroz, M. Rahme, C.H. Van Poznak, T.J. de Villiers, El Hajj Fuleihan, G.: Cancer-associated bone disease. Osteoporos. Int. 24(12), 2929\u20132953 (2013). \n                    https:\/\/doi.org\/10.1007\/s00198-013-2530-3","journal-title":"Osteoporos. Int."},{"issue":"10","key":"1632_CR33","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.amjmed.2010.02.028","volume":"123","author":"G Mazziotti","year":"2010","unstructured":"G. Mazziotti, E. Canalis, A. Giustina, Drug-induced osteoporosis: mechanisms and clinical implications. Am. J. Med. 123(10), 877\u2013884 (2010). \n                    https:\/\/doi.org\/10.1016\/j.amjmed.2010.02.028","journal-title":"Am. J. Med."},{"issue":"3","key":"1632_CR34","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1158\/1055-9965.Epi-07-2747","volume":"17","author":"GG Schwartz","year":"2008","unstructured":"G.G. Schwartz, Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive. Oncology 17(3), 478\u2013483 (2008). \n                    https:\/\/doi.org\/10.1158\/1055-9965.Epi-07-2747","journal-title":"Oncology"},{"issue":"5","key":"1632_CR35","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1634\/theoncologist.2011-0448","volume":"17","author":"A Berruti","year":"2012","unstructured":"A. Berruti, R. Cook, F. Saad, C. Buttigliero, A. Lipton, M. Tampellini, K.A. Lee, R.E. Coleman, M.R. Smith, Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration. Oncologist 17(5), 645\u2013652 (2012). \n                    https:\/\/doi.org\/10.1634\/theoncologist.2011-0448","journal-title":"Oncologist"},{"issue":"1","key":"1632_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-016-3716-2","volume":"28","author":"AA Khan","year":"2017","unstructured":"A.A. Khan, D.A. Hanley, R. Rizzoli, J. Bollerslev, J.E. Young, L. Rejnmark, R. Thakker, P. D\u2019Amour, T. Paul, S. Van Uum, M.Z. Shrayyef, D. Goltzman, S. Kaiser, N.E. Cusano, R. Bouillon, L. Mosekilde, A.W. Kung, S.D. Rao, S.K. Bhadada, B.L. Clarke, J. Liu, Q. Duh, E.M. Lewiecki, F. Bandeira, R. D\u2019Amour, C. Marcocci, S.J. Silverberg, R. Udelsman, K.S. Davison, J.T. Potts Jr., M.L. Brandi, J.P. Bilezikian, Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos. Int. 28(1), 1\u201319 (2017). \n                    https:\/\/doi.org\/10.1007\/s00198-016-3716-2","journal-title":"Osteoporos. Int."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-018-1632-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-018-1632-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-018-1632-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T07:05:14Z","timestamp":1565161514000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-018-1632-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,30]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["1632"],"URL":"https:\/\/doi.org\/10.1007\/s12020-018-1632-2","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,30]]},"assertion":[{"value":"9 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"G.M. received consultant fees from Ipsen and Novartis. S.F. and A.M. have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}}]}}